Type 2 diabetes is a worldwide epidemic. Cardiovascular diseases remain the major cause of death in patients with diabetes, partly because of the association of diabetes and the metabolic syndrome. In this review, we will discuss the evidence for treatment and prevention of cardiovascular diseases in patients with diabetes. Aggressive treatment of hypertension and dyslipidemia is at the cornerstone in the management of heart disease in those patients. Despite its known benefit on the prevention of the microvascular complications of diabetes, intensive glycemic control may or may not have a significant effect on reducing macrovascular diseases. Finally, lifestyle changes and other cardiovascular therapies aimed at preventing heart disease may also prevent or delay the development of diabetes.
T he prevalence of type 2 diabetes is growing rapidly in both the developing and developed worlds, paralleling a rampant increase in obesity. The estimated number of adults with diabetes in the world will rise from 135 million in 1995 to 300 million in year 2025 and the prevalence is expected to rise from 4% in 1995 to 5.4% by the year 2025. 1 In the United States, according to the National Health and Nutrition Examination Survey III published in 1998, the estimated prevalence of diagnosed diabetes is 5.1% and 6.9% for impaired fasting glucose (110 to Ͻ126 mg/dL) for adults more than 20 years of age. 2 Furthermore, diabetes type 2 is now being more frequently diagnosed in children and adolescents in relation to decreased physical activity and increased obesity. 3 Cardiovascular diseases (CVDs) are the leading cause of death in the general population and more so in the diabetic population. Excess risk for CVDs extends to patients with type 1 and type 2 diabetes and to patients with impaired fasting glucose and impaired glucose tolerance. In addition to the increased prevalence of CVDs in patients with diabetes, it appears that diabetic patients suffer a higher fatality rate from CVDs compared with nondiabetic patients. 4 It appears that this excess cardiovascular mortality and morbidity stem at least partly from the very strong association of diabetes and insulin resistance with other cardiovascular risk factors. The evidence supporting the evaluation and treatment of these other cardiovascular risk factors as the cornerstone of primary and secondary prevention of cardiovascular diseases in diabetic patients and will be reviewed below. Beyond strategies for curing diabetes and its cardiovascular complications, a large effort is underway trying to prevent progression to diabetes in patients thought to be at risk. In addition to targeting obesity, physical inactivity, and poor dietary habits, pharmacological preventive therapies are being tested. Interestingly but not surprisingly, various vascular therapies initially prescribed for prevention of various cardiovascular outcomes showed a positive effect on diabetes prevention as well.
tors. This association of various metabolic and hemodynamic abnormalities that we now refer to as the metabolic syndrome has been recognized since it was reintroduced by Reaven in 1988, who labeled it "syndrome X." 5 Ten years later, the World Health Organization (WHO) proposed a formal definition for the metabolic syndrome (see Table 1 ). 6 The risk for coronary artery disease (CAD) and stroke is increased 3-fold in patients with this syndrome. 7 More recently, the Adult Treatment Panel III of the National Cholesterol Evaluation Program recognized the metabolic syndrome, defined somewhat differently, as a secondary target for risk reduction therapies beyond low-density lipoprotein (LDL) lowering, stressing again the importance of therapeutic lifestyle changes ( Table 1 ). 8 EPIDEMIOLOGY Several epidemiological studies have attempted to evaluate the relative contribution of insulin resistance and hyperglycemia to the increased cardiovascular risk in patients with diabetes. These studies have examined the predictive value of various markers of insulin resistance and of hyperglycemia in the development of CVDs in the absence of a diagnosis of diabetes.
Does Insulin Resistance Predict Increased Cardiovascular Risk?
The contribution of insulin resistance per se to increased cardiovascular risk has been highly debated. The difficulty in assessing this relationship arise first from the strong association between insulin resistance and other cardiovascular risk factors as defined by the metabolic syndrome, and second from the difficulty in accurately measuring insulin resistance in large epidemiological studies. A host of longitudinal studies have shown an increased incidence of cardiovascular events in subjects with higher insulin levels, a lessthan-ideal surrogate measure of insulin resistance. A meta-analysis by Ruige and colleagues examining 17 prospective studies evaluating insulin levels (fasting and nonfasting) in relation to cardiovascular outcomes (death from CHD, myocardial infarction, electrocardiogram changes) with follow-up periods ranging from 5 to 11.5 years concluded that insulin levels significantly correlated, although weakly, with incidence of cardiovascular events (relative risk 1.18 [1.08 -1.29]). 9 Yip and associates examined resistance to insulin-mediated glucose disposal, assessed by steady-state glucose levels during an insulin suppression test, in a small healthy nonobese cohort that was followed for an average of 4.7 years. 10 Insulin resistance was found to be an independent predictor of cardiovascular events, even after including various other cardiovascular risk factors in multiple regression models.
The Relation Between Blood Glucose Levels With Cardiovascular Risk: A Threshold or a Continuum?
The causal relationship between hyperglycemia and microvascular disease, as well as the delay or prevention of microvascular complications by improved glycemic control, is well established. However, the relationship between hyperglycemia and macrovascular diseases is less clear. It is known that patients with type 1 diabetes mellitus, where the pathogenesis of hyperglycemia is related to insulin deficiency rather than insulin resistance, have a 3-to 6-fold increase in cardiovascular mortality compared with the general population. 11 Mounting evidence suggests that hyperglycemia even in the nondiabetic range is associated with an increased cardiovascular risk. In a cross-sectional analysis of an elderly population of survivors from the original Framingham cohort, a linear correlation was found between glycosylated hemoglobin concentration (A1C) and prevalent CVD in women (but not in men) even into the nondiabetic range. 12 In a meta-regression analysis of 20 prospective studies of about 95,000 individuals followed for an average of 12.4 years with 3707 cardiovascular events (sudden death, stroke, myocardial infarction), Coutinho et al found a progressive relationship between glucose levels and cardiovascular risk extending below the diabetic threshold. 13 Compared with a fasting blood sugar of 75 mg/dL, a fasting glucose levels of 110 mg/dL (the threshold value for defining impaired fasting glucose) was associated with a relative risk of cardiovascular events of 1.33 (95% confidence interval [CI]: 1.06 -1.67) and a 2-hour glucose of 140 mg/dL, the threshold for defining impaired glucose tolerance was associated with a relative risk of cardiovascular events of 1.58 (95% CI: 1.19 -2.10). Furthermore, in a recent longitudinal analysis in 4664 men aged 45-79 years from the Norfolk cohort of the European Prospective Investigation of cancer and Nutrition, A1C significantly predicted mortality (total and cardiovascular mortality) with increasing risk throughout the range of glucose concentrations even below the usually accepted threshold for diagnosis of diabetes. 14 An increase of 1% in A1C was associated with a 28% (P Ͻ 0.002) increase in risk of death independent of age, blood pressure, serum cholesterol, body mass index, and cigarette smoking. This effect remained significant after exclusion of men with diabetes or history of cardiovascular events. These data taken together suggest that there is no threshold for glycemia in relation to increased cardiovascular risk unlike the relation to increased microvascular risk.
Diabetes Is a Coronary Heart Disease Equivalent
Although the blood glucose levels defining diabetes were chosen to identify subjects at increased risk for microvascular complications, there is no doubt that patients with diabetes are at a very high risk for macrovascular diseases. Epidemiological data [15] [16] [17] suggest that diabetes is associated with a 2-to 4-fold increase in CAD, an increase not accounted for by adjusting for other risk factors. The relative impact of diabetes appears to be substantially greater for women than for men, and the female advantage over men in relation to cardiovascular disease is lost when diabetes is present. Perhaps the strongest evidence of this greatly enhanced cardiovascular risk is from the analysis of the 7-year incidence rates of myocardial infarction among 1373 nondiabetic subjects and 1059 diabetic subjects with or without prior myocardial infarction from a Finnish population-based study. This study showed that diabetic patients without prior myocardial infarction have as high a risk of myocardial infarction as nondiabetic patients with previous myocardial infarction with a 7-year incidence of myocardial infarction of about 20%. 18 Patients with both diabetes and a previous history of myocardial infarction had a 7-year incidence of myocardial infarction of 45%. These findings along with other evidence from lipid trials have lead to the recognition of diabetes as a coronary heart disease risk equivalent in the management of dyslipidemia in the most recent National Cholesterol Evaluation Program recommendations.
TREATMENT BENEFIT IN CARDIOVASCULAR DISEASES

Does Glycemic Control Improve Cardiovascular Outcomes?
It is well established that improved glycemic control results in decreased microvascular complications, 19 -21 but glycemic intervention studies have failed to show significant benefits on macrovascular complications, some even suggesting negative effects. 22 In the Diabetes Control and Complication Trial (DCCT), 19 patients with type 1 diabetes were randomly assigned to intensive versus conventional insulin therapy and followed for 6.5 years for progression or development of retinopathy as primary outcome. However, when all major cardiovascular and peripheral vascular events were combined, intensive therapy reduced the risk of macrovascular disease by 41%, a reduction that did not reach statistical significance perhaps because the low event rate in this young population. 19 In the Epidemiology of Diabetes Interventions and Complications study, which is a long-term observational follow-up of the DCCT cohort, the intima-media thickness (IMT) of the common and internal carotid artery was measured 1 and 6 years after DCCT ended. Controlling for age, gender, smoking, systolic blood pressure at year 1 and baseline IMT, the group who was assigned formerly to the intensive glycemic control had a smaller increase in IMT compared with the conventionally treated group. At year 6, both groups had comparable A1C. 23 In the United Kingdom Prospective Diabetes Studies (UKPDS) 20 where patients with newly diagnosed type 2 diabetes were assigned either to intensive glucose control achieving a median A1C of 7% or to conventional treatment arm achieving an A1C of 7.9% over a median of 10 years of follow-up, there was a 16% reduction in myocardial infarction that did not quite reach statistical significance (P ϭ 0.052). In a secondary analysis of the UKPDS data evaluating the relative risk of glycemic control, using an updated A1C calculated by averaging the baseline and the subsequent yearly A1C values, a 1% drop in updated A1C was not only associated with a 37% reduction for microvascular complications (P Ͻ 0.0001) but also with a substantial reduction in myocardial infarction (14% [8 -21%], P ϭ 0.0001). This suggests that the lower the glycemia over time, the lower the risk of complications including myocardial infarction with no apparent threshold. 24 The Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes, 22 which is a feasibility study for a long-term glycemic control and complications trial currently ongoing, enrolled 153 patients, mean age of 60 years with a mean duration of diabetes of 7.8 years. Patients were randomly assigned to either standard therapy or intensive therapy achieving a 2% difference in A1C between groups (all patients were on insulin). This cohort had a high prevalence of CVD at baseline compared with the UKPDS cohort. After 30 months of follow-up, there were 61 new cardiovascular events in 24 patients (32%) in the intensive treatment arm and in 16 patients (20%) in the standard treatment arm (P ϭ 0.10). There was no difference in total and cardiovascular mortality in this small cohort.
In the Diabetes Insulin/Glucose Infusion in Acute Myocardial Infarction trial, 25 620 diabetic patients with acute myocardial infarction were randomly assigned to routine care with subcutaneous insulin therapy or to a Ն24-hour insulin-glucose infusion followed by multidose subcutaneous insulin for at least 3 months. After 1 year, there was a 29% reduction in mortality in the intensely treated group compared with control. During an average follow-up of 3.4 years, 102 patients (33%) in the intensive insulin group and 138 (44%) in the control group died (P ϭ 0.011). Old age, previous heart failure, diabetes duration, admission blood glucose, and admission A1C were independent predictors of mortality in the total cohort. Intensive insulin treatment achieved reduced long-term mortality despite high admission blood glucose and A1C. 26 In view of these suggestive but inconclusive results in regard to glycemic control and decreased cardiovascular morbidity and mortality, 2 large trials were initiated. The Action to Control Cardiovascular Risk in Diabetes is a multicenter trial of about 10,000 subjects randomizing patients with diabetes to either very tight glycemic control targeting an "nondiabetic" A1C of Ͻ6% or conventional treatment with target A1C between 7 and 7.9%. Similarly, a large study in multiple Veterans Affairs medical centers is ongoing with an A1C goal of Ͻ6% in the tight glycemic control arm. Both trials will assess macrovascular endpoints in relation to intensive glycemic control.
What is the Target Blood Pressure Control and What Is the Evidence Guiding the Choice of Antihypertensive Medications?
It is known that hypertension is more common in diabetic patients than in the general population. The UKPDS demonstrated that tight blood pressure control, achieving a median blood pressure of 144/82 mm Hg compared with 154/87 mm Hg over a median of 8.4 years of follow-up significantly reduced the risk for microvascular complication and stroke but not of myocardial infarction. 27 In a posthoc analysis of the UKPDS data, however, systolic blood pressure as assessed by an updated mean of yearly measurements suggested that with each 10 mm Hg drop in systolic blood pressure was associated with significant 11% reduction in myocardial infarction (P Ͻ 0.0001). 28 The lowest risk was observed in those with systolic blood pressure less than 120 mm Hg. Furthermore in the Hypertension Optimal Therapy trial, 29 subjects, including 1501 patients with diabe-tes, were randomized to diastolic blood pressure goals of Ͻ80 mm Hg, Ͻ85 mm Hg, and Ͻ90 mm Hg. Patients assigned to the lowest blood pressure goal had the lowest cardiovascular events and cardiovascular mortality, although total mortality was not significantly different across the groups. These data combined suggest that perhaps there no lower threshold for blood pressure in patients with diabetes. In its most recent guidelines the sixth report of Joint National Committee on prevention, detection, evaluation, and treatment of hypertension 30 recommend targeting a blood pressure of lower than 130/85 in patients with diabetes and to lower than 125/75 in patients with more than 1 g of proteinuria per day. On the choice of which antihypertensive treatment to use, there is clear evidence that renin-angiotensin system (RAS) blockers (angiotensin-converting enzymes inhibitors or angiotensin receptor blocker) be the first line agents in patients with proteinuria in view of their renal protection effects; both losartan 31 and irbesartan 32, 33 demonstrate this benefit. The strongest evidence for improved overall survival by blockade of the RAS was shown by the Microalbuminuria, Cardiovascular and Renal Outcomes-Heart Outcomes Prevention Evaluation trial. 34 The diabetic subgroup of the Heart Outcomes Prevention Evaluation trial included 3577 subjects who were randomized to placebo or ramipril. To be eligible, patients with diabetes had to have at least 1 other classic cardiovascular risk factor. Exclusion criteria were proteinuria, congestive heart failure, recent myocardial infarction, or stroke. Only 56% of the diabetic subjects had hypertension, and the average blood pressure at baseline was only 142/80 mm Hg. The combined outcome of myocardial infarction, stroke, and cardiovascular deaths was significantly lower in the ramipril-treated group with a relative risk reduction of 25% (P Ͻ 0.0004). Total mortality was also reduced in the same group by 25% (P Ͻ 0.004). This benefit from ramipril was independent of whether patients had history of hypertension, cardiovascular events, microalbumin-uria or whether they had type 1 or type 2 diabetes. This is in agreement with findings from the Captopril Prevention trial, 35 which tested captopril-based antihypertensive therapy versus conventional therapy (thiazides and or beta-blockers). This trial included 572 patients with diabetes. Although there was no significant difference in the primary outcome (all cardiovascular events) between the 2 groups in the overall study population, there was a significant 41% reduction in cardiovascular events in the diabetic subgroup treated with captopril compared with conventional therapy, mostly because of a reduction in myocardial infarction. This is, however, in contrast to earlier finding from the UKPDS, where there was no advantage for captopril use over atenolol in lowering the risk for microvascular or macrovascular diabetic complications. 36 More recently, in the Losartan Intervention for End point reduction in hypertension trial, 37 which compared cardiovascular benefit of the angiotensin receptor blocker losartan versus atenolol, included 1195 (13%) diabetic patients with left ventricular hypertrophy. For a similar blood pressure reduction, the losartantreated group had a significantly lower rate of total and cardiovascular mortality and a statistically nonsignificant trend for lower rates of strokes and myocardial infarctions than the atenolol-treated group. Other trials 38,39 that compared angiotensin-converting enzyme inhibitors to dihydropyridine calcium channel blockers suggested a significant cardiovascular benefit with angiotensin-converting enzyme inhibition.
The Antihypertensive and Lipid-lowering Therapy to Reduce heart Attack Trial is another large trial comparing the effect of various antihypertensive medications on cardiovascular outcomes, the results of which are not yet published. It includes more than 15,000 diabetic subjects and will hopefully shed light on the differential effect of the various antihypertensive regimens. 40 It is worth noting however that most diabetic patients will ultimately need multiple agents over time to control their blood pressure to target levels as shown in the UKPDS 27 and other studies.
What Is the Evidence Guiding Lipid Management in Diabetes?
Although abnormal lipid profiles are very commonly encountered in patients with diabetes, the current recommendation for lipid treatment in the diabetic population stems from post hoc subgroup analysis of lipid intervention trials for secondary prevention of cardiovascular disease. Among these trials, the trial with largest percent of diabetic subjects (25%, n ϭ 627) is the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial in which patients with CAD and with low high-density lipoprotein (HDL) and normal LDL cholesterol (mean of 32 and 112 mg/dL respectively), were assigned to gemfibrozil or placebo. 41 After an average of 5.1 year, a 24% reduction in cardiovascular events was noted in the gemfibrozil arm in association with a 6% increase in HDL and 31% drop in triglycerides and no change in LDL cholesterol. This reduction was not different among diabetic and nondiabetic subjects.
The Scandinavian Simvastatin Survival Study 42 included 202 subjects with diabetes (5%), randomized patients with known CAD and with mean LDL cholesterol of 185 mg/dL to either simvastatin or placebo, excluding patients with triglycerides higher than 220 mg/dL. Treatment with simvastatin raised HDL cholesterol by 8% and lowered LDL cholesterol by 35%. Total and cardiovascular mortality were reduced by 30 and 35%, respectively, compared with placebo in the overall cohort. In the diabetic subgroup, the magnitude of reduction in CHD events was even greater than the nondiabetic subgroup (55% versus 32%), with a trend for a lower total mortality rate that did not reach statistical significance in this relatively small cohort. In the Cholesterol and Recurrent Events study, 43 25% reduction in CHD outcomes (CHD death, nonfatal myocardial infarction, and need for angioplasty and coronary bypass), not significantly different in the diabetic subgroup (586 subjects, 14% of the whole study population). The upper limit of triglycerides for inclusion in this study was 350 mg/dL. Despite reductions in CHD outcomes of about 24%, no significant effect on total mortality was found for either the whole group or the diabetic subgroup. The Long-term Intervention with Pravastatin in Ischemic Disease, 44 a trial that included 782 (9%) diabetic subjects, was designed to evaluate survival benefit of 40 mg of pravastatin in patients with CAD. After a mean follow-up period of 6.1 years, total morality was reduced by 25% with pravastatin compared with placebo, with statistically similar 19% reduction in the diabetic subgroup.
Primary prevention lipid-lowering trials, including the Helsinki Heart trial 45 which used gemfibrozil, the West of Scotland Coronary prevention trial, 46 which used pravastatin, and AFCAPS, TexCAPS, 47 which used lovastatin had very small number of diabetic patients. The Diabetes Intervention study randomized 761 newly diagnosed diabetic patients to clofibrate or placebo. Despite lowering triglycerides there was no effect on clinical cardiovascular outcomes. 48 Other studies were designed to evaluate the effect of lipid interventions on angiographic or ultrasonographic markers of atherosclerosis. The post-CABG 49 study evaluated the effect of aggressive LDL lowering to levels below 100 mg/dL on angiographic progression of atherosclerosis in patient post coronary artery bypass graft. The trial included 116 diabetic patients (9%) who had a higher rate of clinical events than nondiabetic patients (4-year composite event rate of 20.6% versus 13.4% P ϭ 0.033). Diabetic patients, however, had a similar significant benefit in angiographic outcomes and a similar nonstatistically significant trend for fewer clinical events than the nondiabetic patients.
The St Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention 50 was designed to evaluate the effect of bezafibrate on IMT of the carotid and femoral arteries as a surrogate markers for atherosclerosis progression in 164 type 2 diabetic patients with no known cardiovascular disease compared with placebo. Despite a significant improvement in lipid parameters, there was no effect on the progress of ultrasonically measured arterial disease although there was lower rate of probable ischemia in resting electrocardiogram and of myocardial infarction.
The Diabetes Atherosclerosis Intervention Study 51 evaluated subjects with type 2 diabetes with and without clinical CAD by angiography before and after randomization to either fenofibrate or placebo. There was a significantly reduced progression of coronary artery disease by angiographic parameters in the treated group, with a nonsignificant trend for reduction in clinical endpoints. Baseline triglycerides and LDL and HDL cholesterol were about 222 and 131 and 40 mg/ dL, respectively.
More recently, the Heart Protection Study 52 a very large trial of nearly 20,000 subjects, including 5963 diabetic patients (about a third of whom had known coronary heart disease) was published. Subjects were eligible if they had total cholesterol of at least 135 mg/dL, but anyone in whom statin therapy was considered clearly indicated by their own doctor was excluded.
Subjects were randomized to either placebo or 40 mg simvastatin. With an LDL difference of 38 mg/dL between the simvastatin and the placebo-treated group after a mean duration of follow-up of 5 years, there was a significant reduction in total mortality, mostly accounted for by a 17% reduction in vascular death (P Ͻ 0.0001). In the diabetic subgroup, there was a significant 25% reduction in vascular events (P Ͻ 0.0001), statistically similar to that of nondiabetic cohort. Furthermore there was a highly significant risk reduction even in subjects with baseline LDL lower than 100 mg/dL. Studies evaluating the effect of lipid interventions for primary prevention of cardiovascular diseases exclusively in diabetic patients are ongoing. The protocol of the Collaborative Atorvastatin diabetes study 53 has been recently published. It is a multicenter placebo-controlled randomized trial of primary prevention of cardiovascular disease in patients with type 2 diabetes selected with baseline LDL Ͻ160 mg/dL and triglycerides Ͻ600 mg/dL. Other ongoing studies include the Lipids in Diabetes Study and the Fenofibrate Intervention and Event Lowering in Diabetes trial. (See Table 2 for the recommendations of the National Diabetes Education Program.)
Aspirin Therapy
Treatment with aspirin is recommended by the American Diabetes Association (ADA) for secondary prevention of cardiovascular diseases in patients with diabetes and for primary prevention in those with additional risk factor for diabetes. Most recently, the Hypertension Optimal Treatment trial, 29 which included 1501 hypertensive patients with diabetes as discussed above, had also randomized patients to either aspirin (75 mg/day) or placebo. Patients in the aspirintreated arm had a 36% (P ϭ 0.002) lower incidence of myocardial infarction but the reduction in total and cardiovascular mortality did not reach statistical significance.
Similarly, reduction in cardiovascular events was suggested by a meta-analysis of 145 prospective controlled trials, reported by the Anti-Platelet Trialists. 54 In the US Physician's Health Study, 55 which was a primary prevention randomized trial comparing aspirin 325 mg every other day to placebo, a significant reduction in first myocardial infarction in the treated group (including the diabetic subgroup) lead to the early termination of the study.
PREVENTION OF DIABETES AND CARDIOVASCULAR DISEASES
Despite all the recent advances in treatment of diabetes and cardiovascular diseases, achieving a normal metabolic and hemodynamic milieu is often very difficult in diabetic patients. Short of being able to prevent diabetic complications, prevention of diabetes itself is a logical target. In addition to genetic predisposition, lifestyle and dietary factors thought to be modifiable contribute largely to the development of diabetes. In the last decade, 3 carefully performed randomized placebo-controlled trials have shown that with lifestyle changes, diabetes can be prevented in patients known to be at risk. The first study was conducted in China, 56 where 577 subjects with impaired glucose tolerance by the WHO criteria were randomized to either diet, exercise, both diet and exercise, or to a control group. This study included lean individuals with body mass index (BMI) of less than 25 kg/m 2 . After 6 years of followup, in a proportional hazard analysis adjusted for differences in baseline BMI and fasting glucose, the diet, exercise, and diet and exercise interventions were associated with 31% (P Ͻ 0.03), 46% (P Ͻ 0.0005), and 42% (P Ͻ 0.005) reductions in risk of developing diabetes, respectively. In the Finnish Diabetes Prevention trial, 57 522 middle-age men and women who were overweight with average BMI of 31 kg/m 2 and with impaired glucose tolerance (WHO criteria) were ran- The group assigned to metformin had also a lower incidence of new diagnosis of diabetes (31% reduction compared with control, P Ͻ 0.001). These same interventions that are shown to prevent or at least delay the onset of diabetes are also thought to affect other cardiovascular risk factors. Although lifestyle modification is the most natural and probably the safest way to prevent progression to diabetes, it is clearly not easily achieved and not without cost. Many studies are evaluating the effects of various pharmacological interventions other than metformin in the prevention of diabetes. In a recently published study, troglitazone use for 30 months in 266 Hispanic women with history of gestational diabetes (about 70% of them having impaired glucose tolerance at baseline) resulted in a 55% reduction (P ϭ 0.009) in new diagnosis of diabetes compared with placebo. 59 Another multicenter placebo-controlled 60 trial evalu-ated the effect of acarbose, an ␣-glucosidase inhibitor, on diabetes prevention in a 1429 subjects with impaired glucose tolerance. Despite a high drop out rate in the acarbosetreated group because of gastrointestinal side effects, intention-to-treat analysis suggested that treatment with acarbose decreased the new diagnosis of diabetes by 25% (P ϭ 0.002) compared with placebo. A large multicentric placebo-controlled trial 61 is ongoing evaluating the effect of orlistat along with a hypocaloric diet and moderate physical activity on progression to diabetes in obese subjects. Perhaps most interestingly, some recent studies evaluating the efficacy of various vascular therapies including RAS blockers and statins for the prevention of cardiovascular diseases are reporting positive effect on diabetes prevention. A significant metabolic effect of these therapies was not widely expected. In the Captopril Prevention Project trial, 35 treatment of 10,413 hypertensive nondiabetic subjects with captopril resulted in a reduction in new diagnosis of diabetes compared with conventional antihypertensive (␤-blockers or diuretics) after an average follow-up of 6.1 years (RR 0.86, CI: 0.74 -0.99, P ϭ 0.039). The diagnosis of diabetes, a prespecified secondary outcome, was made according to the WHO criteria. Similarly, in a post hoc analysis of the Heart Outcomes Prevention Evaluation trial, 62 which included 5720 patients with vascular disease but with no known diabetes at baseline, treatment with ramipril compared with placebo was associated a 34% (P Ͻ 0.001) reduction in new diagnosis of diabetes (assessed by patient report) after 4.5 years of follow up. Furthermore, in the Losartan Intervention For Endpoint trial, treatment of patients with hypertension and left ventricular hypertrophy but with no known cardiovascular disease with losartan 63 only with pravastatin, in a post hoc analysis of the West of Scotland Coronary Prevention Study. 64 A total of 5974 randomized subjects were included in the analysis (patients with self reported diabetes or with a fasting blood glucose of Ͼ126 mg/dL were excluded). During an average follow-up of 5.5 years, pravastatin use compared with placebo in subjects with no known cardiovascular disease and with elevated LDL cholesterol resulted in 30% reduction in new diagnosis of diabetes (P ϭ 0.042) as defined by the ADA criteria. On going trials including the Prospective Study of Pravastatin in the Elderly at Risk, Diabetes Reduction Assessment with Ramipril and rosiglitazone Medication, and the NAVIGATOR (a multinational randomized trial for the evaluation of nateglinide and valsartan in the prevention of diabetes and cardiovascular outcomes) will be evaluating the effect of these agents on diabetes progression.
The potential of these agents in preventing diabetes is probably multidimensional and beyond blood pressure and LDL lowering. It may involve anti-inflammatory, anticoagulant and endothelial enhancing effects in addition to an insulin sensitizing effect and is beyond the scope of this review. Findings that these vascular therapies prevented or delayed the onset of diabetes do not prove causality of a vascular pathology leading to diabetes. However this clearly reinforces the intimate relationship between diabetes and cardiovascular diseases and stresses the importance of managing diabetes in the context of the metabolic syndrome.
CONCLUSION
With the projected increase in the prevalence of diabetes, the large social and economic burden of cardiovascular morbidity will be a challenge to the society and health care sector. Aggressive treatment of hyperglycemia although appropriately advocated for prevention of microvascular complications, has a modest effect at best on macrovascular outcomes. Treatment of hypertension and dyslipidemia on the other hand, has been convincingly shown to improve cardiovascular morbidity and mortality. Use of RAS blockers and lipid lowering agents are probably beneficial beyond lowering blood pressure and improving dyslipidemia in the prevention of cardiovascular complications and may prove also to be beneficial in the prevention of diabetes itself. Lifestyle changes promoting physical activity and weight loss, in addition to their known cardiovascular benefit will also delay or prevent the development of diabetes. In addition to medical care, a multidisciplinary approach to diabetes, including social support, continuing diabetes education to both physicians and patients, is at the cornerstone of management and preventive care of all diabetes complications. Ongoing trials will answer many of the most pressing questions but the application of the present and future results to individuals and to population with diabetes remains a difficult task owing to the inherent difficulty in achieving the multiple targets in such patients and to relatively limited financial and human resources.
